Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

fluorescent imaging agent cRGD-ZW800-1

An imaging agent composed of the cyclic arginine-glycine-aspartic acid (cRGD)-based peptide derivative cyclo-(RGDyK) conjugated to the near-infrared (NIR) fluorophore ZW800-1, with potential use as a tumor-selective fluorescent imaging agent. Upon administration of the fluorescent imaging agent cRGD-ZW800-1, the cRGD moiety selectively binds to integrins, including alphaVbeta3, alphaVbeta5 and alphaVbeta6, expressed on tumor cells and tumor-associated vascular endothelium. Upon intraoperative fluorescence imaging, tumor cells and tumor-associated vascular endothelium expressing these integrins can be visualized. Integrins are transmembrane glycoproteins upregulated on proliferating tumor vessel endothelial cells and various cancer cells; their overexpression has been associated with neovascularization, differentiation, proliferation of tumor cells, metastasis and an overall poor prognosis.
Synonym:cyclo-(RGDyK)-ZW800-1
Abbreviation:cRGD-ZW800-1
Search NCI's Drug Dictionary